Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind Study to Investigate the Effect of aleglitazar [R1439] on Glycemic Control in Patients With Type 2 Diabetes Mellitus.

Next Previous
Trial Profile

A Randomized, Double-Blind Study to Investigate the Effect of aleglitazar [R1439] on Glycemic Control in Patients With Type 2 Diabetes Mellitus.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aleglitazar (Primary) ; Pioglitazone
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms SYNCHRONY
  • Sponsors Roche

    • Most Recent Events

    • 28 Aug 2010 Pharmacodynamic outcomes were reported at the ESC Congress 2010: Annual Congress of the European Society of Cardiology.
    • 14 Nov 2009 Results of an exploratory analysis on the effects of aleglitazar on cardiovascular markers has been published as an abstract in the proceedings from the 82nd Annual Scientific Sessions of the American Heart Association (AHA).
    • 09 Jun 2009 Results reported at American Diabetes Assocation meeting (ADA 2009), according to a Roche media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top